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Résumé en
anglais
BACKGROUND: Chronic hepatitis B (CHB) is a clinical concern in human
immunodeficiency virus (HIV)-infected individuals due to substantial prevalence,
difficulties to treat, and severe liver disease outcome. A large nationwide cross-
sectional multicentre analysis of HIV-HBV co-infected patients was designed to
describe and identify parameters associated with virological and clinical outcome of
CHB in HIV-infected individuals with detectable HBV viremia.
METHODS: A multicenter collaborative cross-sectional study was launched in 19
French University hospitals distributed through the country. From January to
December 2007, HBV load, genotype, clinical and epidemiological characteristics of
223 HBV-HIV co-infected patients with an HBV replication over 1000 IU/mL were
investigated.
RESULTS: Patients were mostly male (82%, mean age 42 years). Genotype
distribution (A 52%; E 23.3%; D 16.1%) was linked to risk factors, geographic
origin, and co-infection with other hepatitis viruses. This genotypic pattern
highlights divergent contamination event timelines by HIV and HBV viruses. Most
patients (74.7%) under antiretroviral treatment were receiving a drug with anti-
HBV activity, including 47% receiving TDF. Genotypic lamivudine-resistance
detected in 26% of the patients was linked to duration of lamivudine exposure, age,
CD4 count and HIV load. Resistance to adefovir (rtA181T/V) was detected in 2.7%
of patients. Advanced liver lesions were observed in 54% of cases and were
associated with an older age and lower CD4 counts but not with viral load or
genotype. Immune escape HBsAg variants were seldom detected.
CONCLUSIONS: Despite the detection of advanced liver lesions in most patients,
few were not receiving anti-HBV drugs and for those treated with the most potent
anti-HBV drugs, persistent replication suggested non-optimal adherence.
Heterogeneity in HBV strains reflects epidemiological differences that may impact
liver disease progression. These findings are strong arguments to further optimize
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